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Abstract
Hepatitis C virus (HCV) is a blood-borne pathogen that often results in chronic liver infection 
leaving patients at risk for cirrhosis, liver decompensation and hepatocellular carcinoma. The goal of 
therapy is to eliminate the virus in order to minimize morbidity and mortality from HCV infection. 
Traditional treatment has utilized a combination of pegylated-interferon (IFN) and ribavirin that 
often causes both systemic and ocular side effects. The most common ocular side effects are retinal 
hemorrhages and cotton wool spots, although in rare circumstances more significant ophthalmic 
adverse events have been attributed to IFN therapy.  
Here we discuss a case of bilateral anterior ischemic optic neuropathy (AION) that occurred during 
treatment with IFN and ribavirin for HCV genotype 1.  We review the proposed pathogenesis 
of ocular side effects associated with this regimen, as well as the pathogenesis and risk factors 
associated with AION itself. Finally, we will offer clinical recommendations for screening for more 
than retinopathy should a patient present with ophthalmic complications.  
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Introduction 
Hepatitis C virus (HCV) is a blood-borne pathogen 
classified into 6 major genotypes that can cause both acute 
and chronic liver infection. While 15-25% of those infected 
may clear the virus without treatment, the majority of 
individuals will develop chronic liver infection leaving them 
at risk for cirrhosis, liver decompensation, and hepatocellular 
carcinoma.1 It is estimated that chronic HCV infection affects 
between 130-150 million people worldwide.1,2
The goal of therapy is to eliminate the virus in order to 
minimize morbidity and mortality from HCV infection. Until 
recently, the mainstay of therapy has been a combination of 
pegylated-interferon alpha (IFN) and ribavirin over a course 
of 48 weeks.  Side effects of this regimen are essentially 
inevitable and can be quite severe. Rapid advances in HCV 
treatments offer higher cure rates and fewer side effects than 
IFN therapy. However, these emerging therapies are not yet 
widely employed in the treatment of HCV, mainly due to the 
significant cost burden associated with these regimens.3 
The ophthalmic side effects of IFN therapy are well 
established, most commonly involving retinal hemorrhage 
and cotton wool spots, which often go unnoticed due to the 
lack of associated visual disturbance. In rare circumstances, 
more significant ophthalmic adverse events, including central 
retinal vein occlusion (CRVO) and anterior ischemic optic 
neuropathy (AION), have been attributed to IFN therapy. As 
these more ominous ocular sequelae require discontinuation 
of treatment to allow for visual improvement, it would 
behoove the clinical optometrist to be able to recognize these 
adverse events and their association with IFN use.
Case Report
A 55-year-old white male presented to the eye clinic reporting 
a visual disturbance described as “missing spots” in his vision 
for one week. The patient’s ocular history was unremarkable. 
His systemic history was notable for hypertension controlled 
with hydrochlorothiazide/lisinopril 20mg daily and chronic 
hepatitis C genotype 1 treated with ribavirin 1200mg daily 
and pegylated-inferferon alpha-2A injections 180μg weekly. 
The patient had tolerated this therapy well and had no 
detectable virus by his 20th week of treatment.  By his 22nd 
week he developed ribavirin-induced anemia with symptoms 
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including shortness of breath, dizziness and fatigue. These 
symptoms improved with a reduction in dose from 1200mg 
to 800mg daily.  Four weeks prior to his presentation to the 
eye clinic, the patient had developed an intermittent fever with 
myalgia, nausea, vomiting and diarrhea. At that time, he was 
evaluated in the emergency room with a fever of 103.7°F and 
reduced blood pressure measuring 99/66.
At presentation to the eye clinic, the patient was in his 44th 
week of interferon therapy. His visual acuities were 20/30 (6/9) 
in the right eye (OD) and 20/25 (6/7.5) in the left eye (OS). 
The pupils were round and equally reactive to light, without 
an afferent pupillary defect. Confrontation visual fields were 
restricted superiorly in each eye. Slit lamp examination was 
remarkable for trace nuclear sclerotic cataracts bilaterally. 
Goldmann applanation tonometry readings were 9 mm 
Hg OD and 9 mm Hg OS at 9:15am. Blood pressure was 
measured at 112/65 RAS.  Dilated fundus exam revealed 
subtle, sectoral optic disc edema associated with flame-shaped 
hemorrhages. In addition, focal retinal arteriole occlusions 
were present bilaterally (Figure 1).  Automated visual field 
testing demonstrated a superior altitudinal defect in each eye 
corresponding to the areas of greatest optic disc edema.
Given the atypical presence of bilateral optic nerve 
head edema, a MRI was obtained which did not reveal any 
intracranial abnormalities or enhancement of the optic nerves. 
Given the severity of his systemic symptoms, he was admitted 
and underwent an infectious disease workup. The patient was 
ultimately diagnosed with interferon-associated retinopathy 
in conjunction with bilateral non-arteritic anterior ischemic 
optic neuropathy. The findings were relayed to the patient’s 
gastroenterologist with the recommendation to discontinue 
interferon and ribavirin treatment.  
The patient was monitored in the eye clinic over a 6-week 
period, during which time his symptoms subsided, his visual 
acuity returned to 20/20 (6/6) in each eye, and his optic disc 
edema and retinal findings gradually resolved (Figures 2 and 
3). Retinal arteriolar occlusions and anterior ischemic optic 
neuropathy were both considered as contributory to visual 
field loss at presentation. Insofar as the improvement of disc 
edema yielded improvement in the visual field defect, the 
visual field defect was most likely a manifestation of AION.   
Treatment with interferon and ribavirin had yielded an end 
of treatment response with no virus detectable by the 20th week, 
remaining so until treatment was discontinued in his 44th week. 
After treatment was discontinued, the patient relapsed and virus 
was detectable several months later.  Treatment was eventually 
restarted with ledipasvir 90mg/sofosbuvir 400mg (Harvoni) 
and ribavirin 1200mg, both daily. He has had no detectable 
virus at weeks 4, 8 and 12 post-re-initiation of treatment.  
Discussion
Interferons are naturally occurring glycoproteins with anti-viral, 
anti-tumor and anti-angiogenic properties.4,5 For the treatment 
of HCV, IFN is usually administered weekly by subcutaneous 
injection.  Patients on this regimen commonly experience fever, 
chills and flu-like symptoms; nausea, vomiting and systemic 
hypotension can occur, albeit rarely.4,6 Reports of incidence 
of retinopathy vary widely, attributed to differences in study 
design. Lack of formal screening leads to under-reporting, 
while evaluation of symptomatic or at-risk patients leads to 
over-reporting of ocular sequelae.7 Raza et al report the overall 
incidence of retinopathy in patients treated with IFN and 
ribavirin to be approximately 27%; patients with diabetes (DM) 
and hypertension (HTN) are 5 to 6 times more likely to develop 
retinopathy than patients without these systemic conditions.5 
Interferon-associated retinopathy typically occurs 2 to 12 
weeks after initiation of therapy.7 Patients are generally visually 
asymptomatic, but exhibit retinal hemorrhages and/or cotton 
wool spots on dilated fundus examination. These changes 
are proposed to be the end result of disturbances in retinal 
microvascular circulation.8 The pathophysiology is not fully 
understood, but many suggest a role of endothelial dysfunction 
where platelet aggregation with leukocyte adherence to the 
vascular endothelium form microthrombi capable of focal 
microinfarction.7,9-12
Interferons act by binding to receptor cells and initiating the 
production of effector proteins. In the event of an interferon-
associated AION, it is theorized that these circulating proteins 
could lead to hyperviscosity and result in compromised perfusion 
to the capillary beds of the optic nerve head.6 Hayreh has long 
argued that AION results from a transient decrease in perfusion 
of the optic nerve head, usually during sleep, and is therefore 
a hypotensive event rather than an embolic disorder.13-16 
Systemic hypotension is a well-known finding associated with 
IFN treatment. Our patient was hospitalized with a hypotensive 
event in the weeks preceding the onset of visual symptoms.   
No standard recommendations for the screening of patients 
for interferon-associated retinopathy exist. This is likely due 
to the fact that the retinopathy is generally not associated 
with vision loss, follows a benign course, and is self-limiting, 
usually resolving shortly after the completion of the course of 
treatment. In general, most clinicians agree that screening high 
risk patients for interferon-retinopathy is prudent, however, 
O’Day et al suggest that routine screening is unnecessary, 
even for patients with HTN and DM, unless they are visually 
symptomatic.7 As vision loss in patients with identified IFN-
associated retinopathy is rare, treatment is generally continued 
despite retinopathy being identified especially given the greater 
risk to the overall health of a patient with premature cessation 
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of interferon treatment. However, if vision loss occurs during 
treatment, suspicion for a less common adverse event such as 
CRVO or AION should be explored. In such cases, the best 
visual outcome exists with cessation of treatment.12
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Final Thoughts
In the ever-changing landscape of HCV treatment, pegylated-
interferon seems likely to have a reduced presence in many 
treatment protocols, as direct-acting antiviral agents such as 
Sovaldi and Harvoni offer shorter treatment courses, superior 
cure rates, and fewer side effects. However, for a number of 
reasons, including treatment cost, IFN will continue to have 
a place in the armamentarium of HCV treatment, and an 
understanding of potential ocular sequelae associated with this 
regimen remains necessary to allow for optimal care of these 
patients.   
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